Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011

JAMA

Volumn 312, Issue 9, 2014, Pages 902-914

  Kurian, Allison W ^a   Lichtensztajn, Daphne Y ^b   Keegan, Theresa H M ^a,b   Nelson, David O ^a,b   Clarke, Christina A ^a,b   Gomez, Scarlett L ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BILATERAL MASTECTOMY; BREAST CANCER; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CAUCASIAN; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAID; MULTIPLE REGRESSION; NATIONAL HEALTH ORGANIZATION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PROPENSITY SCORE; PUBLIC HEALTH INSURANCE; SURGICAL MORTALITY; TREATMENT OUTCOME; UNILATERAL MASTECTOMY; UNITED STATES;

ADULT; AGED; BREAST NEOPLASMS; CALIFORNIA; COHORT STUDIES; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; RADIOTHERAPY, ADJUVANT; REGISTRIES; RISK; SEER PROGRAM; SURGICAL PROCEDURES, ELECTIVE;

EID: 84907337077     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.10707     Document Type: Article

References (40)

1. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233-1241. (Pubitemid 35176242)
2. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227-1232. (Pubitemid 35176241)
3. Gomez SL, Lichtensztajn D, Kurian AW, et al. Increasing mastectomy rates for early-stage breast cancer? J Clin Oncol. 2010;28(10):e155-e157.
4. Katipamula R, Degnim AC, Hoskin T, et al. Trends in mastectomy rates at the Mayo Clinic Rochester. J Clin Oncol. 2009;27(25):4082-4088.
5. Tuttle TM, Habermann EB, Grund EH, et al. Increasing use of contralateral prophylactic mastectomy for breast cancer patients. J Clin Oncol. 2007;25(33):5203-5209.
6. King TA, Sakr R, Patil S, et al. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol. 2011;29(16):2158-2164.
7. Heemskerk-Gerritsen BA, Menke-Pluijmers MB, Jager A, et al. Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers. Ann Oncol. 2013;24(8):2029-2035.
8. Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol. 2010;28(2): 222-231.
9. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93(21):1633-1637. (Pubitemid 33094870)
10. Barton MB, West CN, Liu IL, et al. Complications following bilateral prophylactic mastectomy. J Natl Cancer Inst Monogr. 2005;(35):61-66.
11. Miller ME, Czechura T, Martz B, et al. Operative risks associated with contralateral prophylactic mastectomy. Ann Surg Oncol. 2013;20(13):4113-4120.
12. Bresser PJ, Seynaeve C, Van Gool AR, et al. Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed women. Plast Reconstr Surg. 2006;117(6):1675-1684.
13. Frost MH, Schaid DJ, Sellers TA, et al. Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA. 2000;284(3):319-324. (Pubitemid 30469858)
14. Procedures for Conducting Data Linkages With the California Cancer Registry. http://www.ccrcal.org/Data-and-Statistics/Cancer-Data-for-Research. shtml. Accessed June 12, 2014.
15. Yost K, Perkins C, Cohen R, et al. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control. 2001;12(8):703-711. (Pubitemid 32803497)
16. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3): 335-351. (Pubitemid 30070608)
17. Austin PC. The use of propensity score methods with survival or time-to-event outcomes. Stat Med. 2014;33(7):1242-1258.
18. McCaffrey DF, Griffin BA, Almirall D, et al. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med. 2013;32(19):3388-3414.
19. Lumley T. Complex Surveys: A Guide to Analysis Using R. Hoboken, NJ: John Wiley & Sons; 2010.
20. Carlson RW, Allred DC, Anderson BO, et al; National Comprehensive Cancer Network. Invasive breast cancer. J Natl Compr Canc Netw. 2011;9(2): 136-222.
21. Bedrosian I, Hu CY, Chang GJ. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst. 2010;102(6):401-409.
22. Kauffmann R, Nelson R, Smith D, et al. Improved survival with contralateral prophylactic mastectomy. Abstract presented at: Society of Surgical Oncology Cancer Symposium; March 13-15, 2014; Phoenix, AZ.
23. Agarwal S, Pappas L, Neumayer L, et al. Effect of breast conservation therapy vs mastectomy on disease-specific survival for early-stage breast cancer. JAMA Surg. 2014;149(3):267-274.
24. Hwang ES, Lichtensztajn DY, Gomez SL, et al. Survival after lumpectomy and mastectomy for early stage invasive breast cancer. Cancer. 2013;119 (7):1402-1411.
25. Herrinton LJ, Barlow WE, Yu O, et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer. J Clin Oncol. 2005;23(19):4275-4286. (Pubitemid 46207002)
26. Yao K, Winchester DJ, Czechura T, Huo D. Contralateral prophylactic mastectomy and survival. Breast Cancer Res Treat. 2013;142(3):465- 476.
27. Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. 2010; (11):CD002748.
28. Griggs JJ, Culakova E, Sorbero ME, et al. Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol. 2007;25(18):2522-2527. (Pubitemid 47041224)
29. Kurian AW, Lichtensztajn DY, Keegan TH, et al. Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007. Breast Cancer Res Treat. 2013;137(1):247-260.
30. Wu AH, Gomez SL, Vigen C, et al. The California Breast Cancer Survivorship Consortium (CBCSC): prognostic factors associated with racial/ethnic differences in breast cancer survival. Cancer Causes Control. 2013;24(10):1821-1836.
31. Kurian AW, Mitani A, Desai M, et al. Breast cancer treatment across health care systems. Cancer. 2014;120(1):103-111.
32. Tuttle TM. Magnetic resonance imaging and contralateral prophylactic mastectomy. Ann Surg Oncol. 2009;16(6):1461-1462.
33. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967-975.
34. Abbott A, Rueth N, Pappas-Varco S, et al. Perceptions of contralateral breast cancer. Ann Surg Oncol. 2011;18(11):3129-3136.
35. Rosenberg SM, Tracy MS, Meyer ME, et al. Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer. Ann Intern Med. 2013;159(6):373-381.
36. Howard-McNatt M, Schroll RW, Hurt GJ, Levine EA. Contralateral prophylactic mastectomy in breast cancer patients who test negative for BRCA mutations. Am J Surg. 2011;202(3):298-302.
37. Daly M. Genetic/Familial High-Risk Assessment: Breast and Ovarian. NCCN Clinical Practice Guidelines in Oncology. http://www.nccn.org. Accessed June 12, 2014.
38. Hawley ST, Jagsi R, Morrow M, et al. Social and clinical determinants of contralateral prophylactic mastectomy [published online May 21, 2014]. JAMA Surg. doi:10.1001/jamasurg.2013.5689.
39. Frost MH, Slezak JM, Tran NV, et al. Satisfaction after contralateral prophylactic mastectomy. J Clin Oncol. 2005;23(31):7849-7856.
40. Schnipper LE, Smith TJ, Raghavan D, et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs. J Clin Oncol. 2012;30(14):1715-1724.